On September 6, 2024, the results of the first substantive examination of Lykos’ U.S. application (US 18/611,564) posted. The Non-Final Office Action (NFOA) introduced a
But the establishment of an expert consensus of standards in psychedelic care would “add legitimacy to the practice”. “Standardisation—of things like training protocols, patient safety,
NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment
The episode began with the retired Republican politician, Perry, recounting the story of how he befriended Marcus Luttrell, a Navy SEAL who ended up living
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. Subscribe AnnuallySubscribe Monthly Already
AJP is the official journal of the American Psychiatric Association (APA), the largest such organisation in the world with around forty thousand members and a global reach.
Despite finalizing the rules over the last 18 months, DORA decided to make a substantial last-minute change to where natural medicine services can take place.
As 2025 begins, the psychedelic industry stands at a critical turning point, with advances in clinical research, regulatory shifts, and growing cultural acceptance reshaping its
The psychedelics industry witnessed notable milestones and setbacks at both the state and federal levels in 2024. Here’s a detailed look at some of the
VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company,